|Bid||0.00 x 1000|
|Ask||0.00 x 21500|
|Day's Range||39.67 - 40.18|
|52 Week Range||37.43 - 50.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.86 (4.64%)|
|1y Target Est||44.00|
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. This has led to an increase in merger & acquisition activity and may boost innovation and capital building in the biotech industry. Earlier in the year, we have seen Sanofi SA (NYSE:SNY) and Celgene Corporation (NASDAQ:CELG) acquiring smaller biotech companies.
An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus. The findings, published on Wednesday in the New England Journal of Medicine, offer fresh support for the World Health Organization recommendation in April that Sanofi's vaccine should not be used without testing for prior dengue exposure. Currently, there are no widely available rapid tests for prior dengue infection.
Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a contender in the next one. A treatment Sanofi is developing with Regeneron Pharmaceuticals Inc. could go on sale by the end of the year, said Joanne Lager, head of oncology development at the Paris-based company.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
TORONTO , June 13, 2018 /CNW Telbec/ - The 21st edition of The Sanofi Canada Healthcare Survey of Canadian employees with workplace health benefit plans (plan members) and of organizations who offer their employees health benefits (plan sponsors) indicates that while 58% of surveyed plan members report having at least one chronic disease or condition, plan sponsors underestimate the proportion of their workforce with a chronic condition (29%). Three-quarters (77%) of plan sponsors indicate they are concerned about the impact of unmanaged chronic disease on the productivity of their workforce.
Sanofi (SASY.PA) believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology. "We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets," Jorge Insuasty, Sanofi's global head of development, told journalists on Wednesday. Sanofi is working on 10 new cancer medicines.
Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology. "We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets," Jorge Insuasty, Sanofi's global head of development, told journalists on Wednesday. Sanofi is working on 10 new cancer medicines.
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi successfully prices USD 2 billion bond issue Paris, France - June 13, 2018 - Sanofi has successfully priced its offering of USD 2 ...
In doing such a capital increase, Sanofi intends to better associate its employees with the future development and results of the company. On March 6, 2018 the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan. The subscription price is €52.66.
NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNH ...
LONDON, UK / ACCESSWIRE / June 6, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Healthcare stocks: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), Sanofi (NYSE: SNY), and TherapeuticsMD Inc. (NASDAQ: TXMD).
want you to know they dropped drug prices last year. The Food and Drug Administration, meanwhile, has said it plans to cut down on drug monopolies to help others lower their prices too. The moves come after President Trump last month ran out a number of concepts to drive prices down that didn't involve going after drug companies but rather focused on shaming the companies into wanting to decrease medication prices.
GUILDFORD, England , June 5, 2018 /PRNewswire/ -- - Patients treated with cemiplimab experienced robust anti-tumour effects - Data also presented today at the 2018 ASCO Annual Meeting, - Cemiplimab applications under review by regulatory authorities in the U.S. and ...
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma ...
PARIS and TARRYTOWN, N.Y., June 4, 2018 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
On May 15, leading pharmaceutical company Novartis (NVS) acquired AveXis, a US-based clinical-stage gene therapy company. This transaction strengthens Novartis’s position as a leader in gene therapy and neuroscience. The chart below summarizes the deal.
GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Regeneron Pharmaceuticals (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
French drug company Sanofi SA says the average price of its medicines fell 8.4% in the U.S. last year after accounting for rebates, the latest example of pharmaceutical pricing pressures. Several major drug companies have now said the net prices of their medicines—that is, the price of the drugs after discounts and rebates—fell in aggregate in 2017. Johnson & Johnson and Merck & Co. have said the sums paid for their drugs had dropped last year, too.
In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.
GlaxoSmithKline (GSK) is focused on maintaining a sustainable growth model by strategizing its business beyond pharmaceuticals.